DELCATH(R) SYSTEMS, INC. LOGO DELCATH SYSTEMS EXTENDS COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT

[DELCATH(R) SYSTEMS, INC. LOGO]

          DELCATH SYSTEMS EXTENDS COOPERATIVE RESEARCH AND DEVELOPMENT
                  AGREEMENT WITH THE NATIONAL CANCER INSTITUTE

    5-YEAR AGREEMENT PROVIDES FOR EXPANDED DEVELOPMENT OF DELCATH'S REGIONAL
                                  CANCER THERAPY

STAMFORD, CT, MARCH 29, 2007-Delcath Systems, Inc. (Nasdaq: DCTH) today
announced that the Company has signed a five year extension to its Cooperative
Research and Development Agreement ("CRADA") with the National Cancer Institute
("NCI"). This extension enhances and expands the initial CRADA that expired in
December 2006. The new five year extension provides for the Company and the NCI
to collaborate in the joint development and evaluation of the Delcath Systems
device to deliver high-dose Melphalan to patients, and to evaluate the
advisability of developing additional commercial agents for use with the Delcath
System, the Company's percutaneous perfusion technology for region-specific
delivery of chemotherapeutic and other therapeutic agents.

Under the new agreement, the Surgery Branch of the NCI will work towards
completion of Delcath System's pivotal ongoing Phase III trial for patients with
metastatic melanoma in the liver using the drug Melphalan, and is expected to
serve as the coordinating center when this study expands to a multi-center
trial. The Phase III study is treating patients with ocular and cutaneous
melanoma who have unresectable tumors in the liver, using the Delcath System to
deliver the drug. The Delcath System is designed to isolate the patient's liver
in order to allow significantly higher dosing of Melphalan while limiting the
systemic toxicities that result from current intravenous chemotherapy
treatments.

Patients in the Phase III trial are randomly assigned to one of two initial
treatment arms, for immediate treatment with Melphalan via the Delcath System,
or alternatively, treatment with best alternative care. The study is designed to
evaluate the duration of tumor response in each of the two arms of the study.
Following the guidelines established by the FDA for this trial under a Special
Protocol Assessment, when the disease progresses (tumor grows) in patients
receiving best alternative care, they are allowed to "cross over" and receive
treatment with the Delcath System. The FDA has approved expansion of the trial
to include up to 15 centers. Upon appropriate NCI Institutional Review Board
("IRB") approval (currently pending), this trial will be expanded to a
multi-center trial.

The NCI will continue conducting the Phase II clinical study of Melphalan in
patients with primary and metastatic hepatic malignancies using the Delcath
System. One of the arms of this multi-histology study was recently expanded to
include twenty-five patients after showing tumor